Abivax presents first-half 2021 financial results and operations update
-
In May and September, Abivax reported excellent efficacy and safety results of once daily oral ABX464 in a phase 2b induction study in ulcerative colitis (UC) after 8 and 16 weeks of treatment, primary and key secondary endpoints were met
-
Abivax also communicated additional maintenance data of ABX464 phase 2a and 2b trials that confirmed long-term efficacy and safety of 50mg once daily oral ABX464 in UC patients
-
In June, Abivax announced that ABX464 met the primary endpoint in a phase 2a study in rheumatoid arthritis (RA) patients and demonstrated a good safety and tolerability profile with 50mg once daily oral administration
-
Abivax is currently evaluating the future clinical development prioritization for ABX464, focusing on the global phase 3 development in UC, to extend the Company’s cash runway from Q2 2022 until the end of Q3 2022
-
Cash for operations strengthened in July with a financing of EUR 85M secured by the pricing of an oversubscribed capital increase of EUR 60M and convertible bonds of EUR 25M
-
On October 4, at UEG Week Virtual 2021, a late-breaking abstract on ABX464 phase 2b data in UC will be presented and Abivax will also be hosting a Live Industry Symposium at the conference